Navigation Links
Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
Date:6/9/2009

atal myocardial infarction and stroke in patients with type 2 diabetes. The approach in this selected high-risk patient population will be unique as no drug has been demonstrated to reduce cardiovascular risk in type 2 diabetes patients following an ACS event.

Professor Robert Henry, SYNCHRONY Clinical Investigator and Chief VA Endocrinology & Metabolism and Professor of Medicine in Residence at the University of California at San Diego, commented: "The favorable balance in the safety and efficacy profile of aleglitazar seen in the SYNCHRONY study represents encouraging short-term clinical data for this agent and provides good evidence to enter Phase III investigation."

With the decision to move into Phase III, aleglitazar is Roche's third Phase III clinical trial program in the area of metabolism. The new Phase III study is a cardiovascular outcomes trial designed to assess the potential of once-daily 150 micrograms aleglitazar to reduce cardiovascular mortality, non-fatal myocardial infarction and stroke in type 2 diabetes patients with a recent ACS.

About the SYNCHRONY Study

SYNCHRONY was a multicenter, randomized, double-blind, placebo-controlled dose ranging study among 332 type 2 diabetes patients (either drug-naive or pre-treated with less than or equal to 2 oral agents). Designed to determine the glucose-lowering and lipid-modifying effects, and safety profile of aleglitazar, the study confirmed the favorable safety and efficacy profile of the once daily 150 microgram aleglitazar dose and supported commencement of the Phase III clinical investigation.

Patients underwent a single-blind 4- to 5-week placebo run-in period, then were randomized to receive 16 weeks treatment with either aleglitazar at one of four once daily doses (50, 150, 300 or 600 micrograms), placebo or 45 mg pioglitazone.

The primary endpoint of dose-dependent reduction
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
2. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
3. Roches Pierson Honored as 2009 HBA Rising Star
4. Corporate Pandemic Preparedness Experts from Roche & PSEG to Advise Savvy Business Leaders May 15
5. Roche Women Honored as 2009 TWIN Awardees
6. Rochester Medical Reports Second Quarter Results
7. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
8. Roche Announces New Co-pay Program in Pennsylvania that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
9. Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
10. Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
11. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... ... women and men - have not brought the anticipated decline in deaths from these diseases, ... Science Center at San Antonio in an opinion piece published in the "Journal of the ... (Vocus) ...
... ROSEMONT, Ill., Oct. 20 Prevalence of lactose intolerance may ... in the latest issue of Nutrition Today .(1) ... of three ethnic groups, reveals that the overall prevalence rate ... percent of European Americans, 10.05 percent of Hispanic Americans and ...
... HOPKINTON, Mass., Oct. 20 Caliper Life Sciences, Inc. ... discussing the company,s third quarter 2009 financial results at ... Hrusovsky, President and Chief Executive Officer and Peter McAree, ... discuss operational and financial results and the company,s outlook ...
... of patients in U.S. hospitals fail to get recommended ... -- A recommended treatment for heart failure is underused ... use of aldosterone antagonist therapy in patients with heart ... heart failure guidelines established by the American College ...
... has heart failure or stroke, study finds , TUESDAY, Oct. ... heart failure and stroke -- and probably their close relatives ... fractures, a new study has found. , Genetic factors might ... shared by the vasculature [blood vessels] and bone," said Dr. ...
... ... annual North American East Coast Rhapsody User Group in Boston, at The Liberty Hotel ... vendor partners showcasing how they utilize Rhapsody to connect and exchange data with other ... Boston, ...
Cached Medicine News:Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 2Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 3Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 4Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 5Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 6Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 2Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 3Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 4Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 5Health News:Caliper Life Sciences' Third Quarter 2009 Financial Results Conference Call Notice 2Health News:Heart Failure Treatment Underused 2Health News:Genes May Link Hip Fractures and Heart Disease 2Health News:Genes May Link Hip Fractures and Heart Disease 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 2Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 4
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... The AMS Ambicor is a uniquely designed ... of cylinders implanted in the corpora cavernosa ... the scrotum. Patients simply squeeze the pump ... deflate the prosthesis. This closed, fluid-filled system ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... on delicate urethral tissues. The ... coating provide nearly friction-free movement, ... easy to maintain sterility. You ... its own sterile water, avoiding ...
Medicine Products: